[Prevention and treatment of bisphosphonate-induced jaw bone osteonecrosis. II].
出版信息
Fogorv Sz. 2014 Sep;107(3):106-7.
PMID:25509512
Abstract
摘要
相似文献
1
[Prevention and treatment of bisphosphonate-induced jaw bone osteonecrosis. II].
Fogorv Sz. 2014 Sep;107(3):106-7.
2
Preventing medication-related osteonecrosis of the jaw.
BMJ. 2019 May 8;365:l1733. doi: 10.1136/bmj.l1733.
3
Bisphosphonate-related osteonecrosis of the jaw in patients with breast cancer.
Eur J Orthop Surg Traumatol. 2015 Jan;25(1):29-37. doi: 10.1007/s00590-013-1293-z. Epub 2013 Sep 14.
4
["Prevention and treatment of mandibular osteonecrosis due to bisphosphonates" -- interdisciplinary forum].
Fogorv Sz. 2010 Mar;103(1):27-8.
5
[Bisphosphonate-related osteonecrosis of the jaw].
Semergen. 2014 Apr;40(3):143-8. doi: 10.1016/j.semerg.2013.05.005. Epub 2013 Sep 1.
6
Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates.
Anticancer Res. 2014 May;34(5):2477-80.
7
Emerging concepts in the management and treatment of osteonecrosis of the jaw.
Oral Maxillofac Surg Clin North Am. 2013 Feb;25(1):11-20, v. doi: 10.1016/j.coms.2012.10.002. Epub 2012 Nov 13.
8
Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Oct;102(4):433-41. doi: 10.1016/j.tripleo.2006.06.004. Epub 2006 Jul 31.
9
Bisphosphonate holidays.
Drug Ther Bull. 2021 Mar;59(3):35-36. doi: 10.1136/dtb.2020.000057.
10
Incidence of bisphosphonate-related osteonecrosis of the jaw in consideration of primary diseases and concomitant therapies.
Anticancer Res. 2013 Sep;33(9):3917-24.
Zotero 插件